

Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 30 September 2025

	30.09.2025	31.12.2024
	BGN'000	BGN'000
Non-current assets		
Property, plant and equipment	33 362	33 304
Intangible Assets and Goodwill	3 638	2 836
Trade receivables	5 403	5 403
Non-current assets	42 403	41 543
 Inventories	 16 742	 15 862
Trade and other receivables	74 386	70 823
Current tax assets	-	129
Cash and cash equivalents	372	140
Current Assets	91 500	86 954
Assets	133 903	128 497
 Issued capital	 95 900	 91 800
Statutory reserve	13 549	13 097
Retained earnings	6 591	4 545
Equity	116 040	109 442
<i>Equity Attributable to owners of the parent company</i>	<i>116 040</i>	<i>109 442</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
 Long term borrowings	 1 146	 675
Deferred tax liabilities	1 198	1 198
Non-current provisions for employee benefits	268	268
Non-current liabilities	2 612	2 141
 Trade and other payables	 3 896	 6 337
Short term borrowings	10 700	10 454
Current tax liabilities	655	123
Current liabilities	15 251	16 914
Liabilities	17 863	19 055
Equity and liabilities	133 903	128 497

Date of preparation: 24.11.2025

Executive director:

Biser Georgiev

Prepared by:

Tsvetelina Pandeva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as 30 September 2025

	30.09.2025	30.09.2024
	BGN'000	BGN'000
Revenue	47 984	40 414
Other income	2	182
Total income	47 986	40 596
Carrying amount of goods sold	(2 260)	(1 953)
Changes in inventories of finished products and work in progress	14	318
Materials and services	(17 841)	
Personnel expenses	(27 826)	(24 712)
Depreciation / amortisation expenses	(7 868)	(6 664)
Other expenses	(2 129)	(1 877)
Finance income	(470)	(434)
Finance costs	78	40
Total expenses	(432)	(550)
Profit Loss before tax	(40 893)	(35 832)
Current tax expense income		
Profit Loss	7 093	4 764
<i>Profit Loss attributable to owners of the parent company</i>	(495)	(420)
<i>Profit Loss attributable to non-controlling interests</i>		
Other comprehensive income	6 598	4 344
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>	6 598	4 344
Comprehensive income	0.07	0.05
<i>Profit Loss attributable to owners of the parent company</i>	6 598	4 344
<i>Profit Loss attributable to non-controlling interests</i>	-	-
Earnings per share / in BGN per 1 share /	0.07	0.05

Date of preparation: 24.11.2025

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 30 September 2025

	30.09.2025	30.09.2024
	BGN'000	BGN'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	35 433	30 227
Payments to suppliers for goods and services	(19 061)	(15 642)
Payments to and on behalf of employees	(8 020)	(6 832)
Income taxes paid classified as operating activities	(366)	(408)
Other cash payments from operating activities	(6 062)	(4 730)
Cash flows from used in operating activities	1 924	2 615
Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(975)	(1 687)
Cash flows from used in investing activities	(975)	(1 687)
Cash flows from financial activities		
Dividends paid classified as financing activities	341	438
Proceeds from borrowings classified as financing activities	(343)	(446)
Repayments of borrowings classified as financing activities	(323)	(428)
Payments of lease liabilities classified as financing activities	(392)	(391)
Cash flows from used in financial activities	(717)	(827)
Increase/Decrease in cash and cash equivalents	232	101
Cash and cash equivalents	140	73
Cash and cash equivalents	372	174

Date of preparation: 24.11.2025

Executive director:

Biser Georgiev

Prepared by:

Tsvetelina Pandeveva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 30 September 2025

	Issued capital	Property plant and equipment revaluation surplus	Other reserves	Retained earnings	Equity abstract	Equity Attributable to owners of the parent company	Non- controlling interest in equity
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Balance as of 01.01.2024	84 500	4 369	8 431	7 701	105 001	105 001	-
Profit Loss				4 490	4 490	4 490	-
Other comprehensive income		(49)					-
Comprehensive income		(49)		4 490	4 441	4 441	-
Increase/Decrease through appropriation of retained earnings	7 300		347	(347)			-
Total income expense	7 300		347	(7 647)			-
Balance as of 31.12.2024	91 800	4 320	8 778	4 544	109 442	109 442	-
Balance as of 01.01.2025	91 800	4 320	8 778	4 544	109 442	109 442	-
Profit Loss	-	-	-	6 598	6 598	6 598	-
Other comprehensive income	-	-	-				-
Comprehensive income	-	-	-	6 598	6 598	6 598	-
Increase/Decrease through appropriation of retained earnings	4 100	-	451	(4 551)-	-	-	-
Total income expense	4 100	-	451	(4 551)	-	-	-
Balance as of 30.09.2025	91 800	4 320	9 229	6 591	116 040	116 040	-

Date of preparation: 24.11.2025

Executive director:


 Biser Georgiev

Prepared by:



Tsvetelina Pandeva